Clinical Trial Results:
A phase III, open, controlled study to evaluate immunogenicity of GSK Biologicals’ MenACWY-TT conjugate vaccine administered intramuscularly to at risk subjects from 1 to less than 18 years and to an age-matched control group of healthy subjects
Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.
Summary
|
|
EudraCT number |
2011-002410-36 |
Trial protocol |
CZ Outside EU/EEA |
Global end of trial date |
03 Mar 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 May 2016
|
First version publication date |
27 May 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
115524
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01641042 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
GlaxoSmithKline Biologicals
|
||
Sponsor organisation address |
Rue de l’Institut 89, Rixensart, Belgium, B-1330
|
||
Public contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
|
||
Scientific contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-000429-PIP01-08 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
03 Mar 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
10 Oct 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
03 Mar 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate the immunogenicity of 1 and 2 doses of MenACWY-TT administered to at risk subjects compared to age-matched healthy subjects in terms of rSBA and hSBA vaccine response rates for N. meningitidis serogroups A, C, W-135 and Y.
|
||
Protection of trial subjects |
All subjects were supervised for 30 minutes after vaccination/product administration with appropriate medical treatment readily available. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed-up for 31 days after the last vaccination/product administration.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
10 Sep 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Czech Republic: 62
|
||
Country: Number of subjects enrolled |
United States: 24
|
||
Worldwide total number of subjects |
86
|
||
EEA total number of subjects |
62
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
36
|
||
Adolescents (12-17 years) |
50
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
- | |||||||||
Pre-assignment
|
||||||||||
Screening details |
During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms. | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overall Period
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Non-randomised - controlled
|
|||||||||
Blinding used |
Not blinded | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
Nimenrix™ At risk Group | |||||||||
Arm description |
Subjects with an increased risk for meningococcal disease such as anatomic asplenia or some degree of functional asplenia received two doses of the MenACWY-TT vaccine at Visit 1 (Month 0) and Visit 3 (Month 2). | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
NimenrixTM
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
Meningococcal vaccine GSK134612
|
|||||||||
Pharmaceutical forms |
Powder and solvent for solution for injection
|
|||||||||
Routes of administration |
Intramuscular use
|
|||||||||
Dosage and administration details |
2 doses administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
|
|||||||||
Arm title
|
Nimenrix™ Healthy Group | |||||||||
Arm description |
Subjects age matched with the subjects in the At-risk Group received two doses of the MenACWY-TT vaccine at Visit 1 (Month 0) and Visit 3 (Month 2). | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
NimenrixTM
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
Meningococcal vaccine GSK134612
|
|||||||||
Pharmaceutical forms |
Powder and solvent for solution for injection
|
|||||||||
Routes of administration |
Intramuscular use
|
|||||||||
Dosage and administration details |
2 doses administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nimenrix™ At risk Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects with an increased risk for meningococcal disease such as anatomic asplenia or some degree of functional asplenia received two doses of the MenACWY-TT vaccine at Visit 1 (Month 0) and Visit 3 (Month 2). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nimenrix™ Healthy Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects age matched with the subjects in the At-risk Group received two doses of the MenACWY-TT vaccine at Visit 1 (Month 0) and Visit 3 (Month 2). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Nimenrix™ At risk Group
|
||
Reporting group description |
Subjects with an increased risk for meningococcal disease such as anatomic asplenia or some degree of functional asplenia received two doses of the MenACWY-TT vaccine at Visit 1 (Month 0) and Visit 3 (Month 2). | ||
Reporting group title |
Nimenrix™ Healthy Group
|
||
Reporting group description |
Subjects age matched with the subjects in the At-risk Group received two doses of the MenACWY-TT vaccine at Visit 1 (Month 0) and Visit 3 (Month 2). |
|
||||||||||||||||||||||
End point title |
Number of subjects with a vaccine response to rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY antibodies [1] | |||||||||||||||||||||
End point description |
Vaccine response to rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY is defined as rSBA antibody titers ≥1:32, for initially seronegative subjects (i.e. pre-vaccination rSBA antibody titres <1:8) and at least a 4-fold increase in rSBA antibody titres from pre to post-vaccination for initially seropositive subjects (i.e. pre-vaccination rSBA antibody titres ≥1:8).
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
At 1 month post first vaccine dose
|
|||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Number of subjects with a vaccine response to hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY antibodies [2] | |||||||||||||||||||||
End point description |
Vaccine response to hSBA-MenA, hSBA-MenC, rSBA-MenW-135 and hSBA-MenY is defined as hSBA antibody titers ≥1:8, for initially seronegative subjects (i.e. pre-vaccination hSBA antibody titres <1:4) and at least a 4-fold increase in hSBA antibody titres from pre to post-vaccination for initially seropositive subjects (i.e. pre-vaccination hSBA antibody titres ≥1:4).
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
At 1 month post first vaccine dose
|
|||||||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Number of subjects with a vaccine response to rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY antibodies [3] | |||||||||||||||||||||
End point description |
Vaccine response to rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY is defined as rSBA antibody titers ≥1:32, for initially seronegative subjects (i.e. pre-vaccination rSBA antibody titres <1:8) and at least a 4-fold increase in rSBA antibody titres from pre to post-vaccination for initially seropositive subjects (i.e. pre-vaccination rSBA antibody titres ≥1:8).
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
At 1 month post second vaccine dose
|
|||||||||||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Number of subjects with a vaccine response to hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY antibodies [4] | |||||||||||||||||||||
End point description |
Vaccine response to hSBA-MenA, hSBA-MenC, rSBA-MenW-135 and hSBA-MenY is defined as hSBA antibody titers ≥1:8, for initially seronegative subjects (i.e. pre-vaccination hSBA antibody titres <1:4) and at least a 4-fold increase in hSBA antibody titres from pre to post-vaccination for initially seropositive subjects (i.e. pre-vaccination hSBA antibody titres ≥1:4).
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
At 1 month post second vaccine dose
|
|||||||||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY titers equal to or above the cut-off values | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers equal to or above (≥) 1:8.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At pre, post first vaccine dose and post second vaccine dose
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY titers equal to or above the cut-off values | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers equal to or above (≥) 1:128.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At pre, post first vaccine dose and post second vaccine dose
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Antibody titers for rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY meningococcal antigens | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers were measured in Geometric mean titers (GMTs).
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At pre, post first vaccine dose and post second vaccine dose
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects with hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY titers equal to or above the cut-off values | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers equal to or above (≥) 1:4.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At pre, post first vaccine dose and post second vaccine dose
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects with hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY titers equal to or above the cut-off values | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers equal to or above (≥) 1:8.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At pre, post first vaccine dose and post second vaccine dose
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Antibody titers for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY meningococcal antigens | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers were measured in Geometric mean titers (GMTs).
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At pre, post first vaccine dose and post second vaccine dose
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects with anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY antibody concentrations equal to or above the cut-off values | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers equal to or above (≥) 0.3 µg/mL.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At pre, post first vaccine dose and post second vaccine dose
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects with anti-PSA, anti-PSC, anti-PSW-135 and anti-PSY antibody concentration equal to or above the cut-off values | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers equal to or above (≥) 2.0 µg/mL.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At pre, post first vaccine dose and post second vaccine dose
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Antibody titers for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY meningococcal antigens | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody titers were measured in Geometric mean concentrations (GMCs).
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At pre, post first vaccine dose and post second vaccine dose
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects reporting any and grade 3 solicited local symptom at age stratum 1-5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
During the 4-day (Days 0-3) post-vaccination period following each dose and overall
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects reporting any and grade 3 solicited local symptom at age stratum 6-17 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
During the 4-day (Days 0-3) post-vaccination period following each dose and overall
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects reporting any, grade 3 and related solicited general symptoms at age stratum 1-5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptoms = symptoms which prevented normal everyday activities. Grade 3 fever = oral temperature >39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
During the 4-day (Days 0-3) post-vaccination period following each dose and overall
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of subjects reporting any, grade 3 and related solicited general symptoms at age stratum 6-17 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache and fever. Gastrointestinal symptoms include nausea, vomiting, diarrhoea and/or abdominal pain. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptoms = symptoms which prevented normal everyday activities. Grade 3 fever = oral temperature >39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
During the 4-day (Days 0-3) post-vaccination period following each dose and overall
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of subjects reporting New Onset of Chronic Illnesses (NOCIs) | ||||||||||||
End point description |
New Onset of Chronic Illnesses such as autoimmune disorders, asthma, type 1 diabetes and allergies.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From vaccination (dose 1) until the end of the Extended Safety Follow-Up (ESFU)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of subjects reporting any unsolicited adverse events (AEs) | ||||||||||||
End point description |
An unsolicited adverse event (AE) covers any untoward medical occurrence in a clinical subject investigation temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an AE reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
During the 31-day (Days 0-30) post first vaccination period
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of subjects reporting any unsolicited AEs | ||||||||||||
End point description |
An unsolicited AE covers any untoward medical occurrence in a clinical subject investigation temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an AE reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
During the 31-day (Days 0-30) post second vaccination period
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of subjects with serious adverse events (SAEs) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From vaccination (dose 1) until the end of ESFU.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Solicited symptoms during the 4-day (Days 0-3) post-vaccination period, Unsolicited AEs during the 31 Day (Days 0-30) post-vaccination period, SAEs from Dose 1 up to the end of the Extended Safety Follow-Up (ESFU).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The number of occurrences reported for solicited symptoms, adverse events, and serious adverse events were not available for posting. The number of subjects affected by each specific event was indicated as the number of occurrences.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nimenrix™At risk Group
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects with an increased risk for meningococcal disease such as anatomic asplenia or some degree of functional asplenia received two doses of the MenACWY-TT vaccine at Visit 1 (Month 0) and Visit 3 (Month 2). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nimenrix™ Healthy Group
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects age matched with the subjects in the At-risk Group received two doses of the MenACWY-TT vaccine at Visit 1 (Month 0) and Visit 3 (Month 2). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. [13] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: The analysis was performed on the Total vaccinated cohort, only on subjects with their symptom sheets completed. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
01 Apr 2014 |
Amendment 2
Interference had been observed when Menactra and the pneumococcal conjugate vaccine PCV7 were co-administered in subjects < 2 years of age. In order not to compromise the immunogenicity of PCV, the Advisory Committee on Immunization Practices (ACIP) had formulated vaccination recommendations for children aged 9 through 23 months. Following these recommendations, children < 2 years of age with functional or anatomic asplenia were not enrolled in the study. Only children < 2 years of age with complement component deficiencies were enrolled in the ‘At risk’ group in this study.
|
||
01 Apr 2014 |
Amendment 3
The physicochemical stability data on the reconstituted MenACWY-TT vaccine has been complemented by microbial stability data, simulating a contamination that may potentially happen during the reconstitution of the vaccine. These microbial data do not support the use of the vaccine up to 24 hours after reconstitution. Therefore, the storage condition of keeping the reconstituted MenACWY-TT vaccine in the refrigerator for up to 24 hours was removed from the protocol and a reference to the Study Procedures Manual was added for further details. In order to reflect this change, the Study Procedures Manual was modified as well.
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |